High dose of erythropoietin in management of interferon/ribavirin induced anemia

Hepatogastroenterology. 2007 Dec;54(80):2181-3.

Abstract

Accumulating evidence now supports the use of recombinant human erythropoietin (rHuEPO) to manage anemia in PEG-IFN/RBV treated patients, with the objective of maintaining the RBV dose, but currently no official guidelines exist. Actually, rHuEPO exact utilizable dose in PEG-IFN/RBV treated patients is not known. We describe the case of a patient with severe ribavirin-induced anemia.

Publication types

  • Case Reports

MeSH terms

  • Alanine Transaminase / blood
  • Anemia / drug therapy*
  • Antiviral Agents / adverse effects*
  • Antiviral Agents / therapeutic use
  • Aspartate Aminotransferases / blood
  • Erythropoietin / administration & dosage*
  • Female
  • Hematocrit
  • Hemoglobins / analysis
  • Hepatitis C / drug therapy
  • Humans
  • Middle Aged
  • Recombinant Proteins
  • Ribavirin / adverse effects*
  • Ribavirin / therapeutic use

Substances

  • Antiviral Agents
  • Hemoglobins
  • Recombinant Proteins
  • epoetin beta
  • Erythropoietin
  • Ribavirin
  • Aspartate Aminotransferases
  • Alanine Transaminase